Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009
Additional Analyses Showed Pramlintide
Improved Treatment Satisfaction and Quality of Life
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced data showing that the use of mealtime SYMLIN(R) (pramlintide acetate) injection improved gluc...
Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
...:30 PM ET).
Poster: "Clinical and Patient Reported Outcomes in Adults with Type 2 Diabetes on Basal Insulin Randomized to Addition of Mealtime pramlintide
or Rapid-Acting Insulin" will be presented by Mark Peyrot, Ph.D. during a poster session on Saturday, June 6 from 11:30 AM - 1:30 PM CT (12:30 - 2:30 ...
Pipeline for New Obesity Therapies is Focus of New Report
...ide; Amylin/Lilly), exenatide LAR
(Lilly/Amylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin;
Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide
+ AC162352 (PYY
3-36; Amylin), liraglutide (NN2211; Novo Nordisk), albiglutide (GSK / Human
Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-78...
Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
...his report: metformin, Januvia/Janumet
(sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR
(Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide
(Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda),
saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo
GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
...ion and other meetings show that
GlycoMark is particularly valuable in detecting underlying treatment
effects of agents such as exenatide (Byetta) and pramlintide
were not revealed by the gold standard hemoglobin A1C test. These findings
have important implications for patient care and pharmaceuti...
Pramlintide-A Boon to Restrain Fast Food Consumption
...g and the desire to eat high-fat foods and sweets. pramlintide
is the synthetic form of amylin, a satiety hormone...the pancreas, which also produce insulin.
treatment reduces 24-hour caloric intake and meal ... partnership with insulin to regulate blood sugar. pramlintide
is also under development as a potential drug for ...
Pramlintide in Medical Technology
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
...45 p.m. ET).
3. Poster 323-P: "Safety of 360 ug pramlintide
BID treatment for up to 2 years" will be pres...g scale scores in obese subjects treated with pramlintide
as monotherapy and in combination with oral w...ut Pramlintide/Metreleptin Combination Treatment
acetate is a synthetic analog of the natural hormo...
DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes
... Additional Studies Indicate GlycoMark May Be a More Effective Monitor Than
Hemoglobin A1C of Exenatide, Sitagliptin, pramlintide
and Prandial Insulin Therapies in Certain Diabetic Populations
SAN FRANCISCO, June 7 /PRNewswire/ -- GlycoMark, Inc. announced today
Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
...st that metreleptin may be an
effective partner to pramlintide
in the treatment of obesity.
The full paper, pub... to the development of obesity treatments.
is a synthetic analog of amylin, a neurohormone se...
Amylin Pharmaceuticals to Present New Data from Broad Diabetes and
Obesity Programs at ADA 2007
presented by Jonathan Roth, Ph.D. on Monday, June 25 at 3:45 PM CT
(4:45 PM ET).
6. Oral: "Sustained Weight Loss Following 1-y pramlintide
Treatment as an
Adjunct to Lifestyle Intervention in Obesity" will be presented by
Steven Smith, M.D. on Monday, June 25 at 5:30 PM CT...
Pramlintide in Biological News
FDA Approves New Drug to Treat Type I and Type II Diabetes
Symlin should not be used if patients cannot tell when their blood sugar is low, have gastroparesis (slow stomach emptying), or are allergic to pramlintide
acetate, metacresol, D-mannitol, acetic acid, or sodium acetate.
Side effects associated with Symlin include but are not limited to nausea, vomitin...
Pramlintide in Biological Technology